Stock Pick

Regis Healthcare grows revenue and cash flow in H1 FY26 earnings

Written by

openjargon

in

healthcare worker overseeing group of aged care residents at table

The Regis Healthcare Ltd (ASX: REG) share price is in focus after the company delivered an 18% lift in revenue in its H1 FY26 result.

What did Regis Healthcare report?

  • Revenue from services grew 18% to $667.7 million.
  • Underlying EBITDA increased 4% to $70.6 million.
  • Underlying NPAT edged up 0.1% to $29.7 million, while statutory NPAT fell to $13.4 million due to one-off costs.
  • Net operating cash flow jumped 40% to $291.7 million.
  • Interim dividend of 9.0 cents per share (100% franked), payable 9 April 2026.
  • Net cash position improved 10% to $198.0 million.

What else do investors need to know?

Regis reported mature homes average occupancy of 96.0%, with total occupied bed days rising 7%. The company benefited from increased government funding, improved room pricing, and recent acquisitions, which expanded its national portfolio by over 1,000 beds.

Several one-off expenses, including $12.8 million in acquisition and integration costs, impacted statutory profits. Capital expenditure reached $102.1 million, focused on acquisitions, property upgrades, and progressing greenfield developments at Toowong and Carlingford.

Staff levels increased to meet mandated care targets, while staff turnover dropped to 20.2%. The acquisitions of Rockpool and OC Health have been integrated and are expected to contribute positively in future periods.

What did Regis Healthcare management say?

Managing Director and CEO Dr Linda Mellors said:

Our half-year results demonstrate the resilience and momentum of the business as we continue to operate in a rapidly evolving operating environment. We remain focused on delivering high-quality care while advancing our growth strategy, supported by high occupancy and continued investment in our people and service offering. Revenue growth was driven by higher AN-ACC pricing, improved occupancy, and the recent acquisitions of Ti Tree Operations Pty Ltd (Ti Tree), Rockpool and OC Health, collectively adding eight homes and over 1,000 beds to our national portfolio. We also delivered an exceptional cashflow result, driven by increased net RAD cash inflows, reinforcing the strength of our market position.

What’s next for Regis Healthcare?

Regis is targeting growth to 10,000 quality beds by FY28, through a mix of greenfield projects and acquisitions. An active development pipeline is expected to add 300–450 beds from new builds by FY28, with the remainder from M&A.

The company expects continued benefits from aged care funding reforms and demographic shifts. It is guiding to FY26 underlying EBITDA in the range of $130 million to $135 million as it executes its growth strategy, supported by a strong balance sheet.

Regis Healthcare share price snapshot

Over the past 12 months, Regis Healthcare shares have risen 1%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

View Original Announcement

The post Regis Healthcare grows revenue and cash flow in H1 FY26 earnings appeared first on The Motley Fool Australia.

Should you invest $1,000 in Regis Healthcare Limited right now?

Before you buy Regis Healthcare Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Regis Healthcare Limited wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys…

See the 5 Stocks

* Returns as of 20 Feb 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

More posts